Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Status of α-emitter Radioimmunoconjugates for Targeted Therapy

Author(s): Rabiei Mobina, Ahmad Reza Vaez Alaei and Hassan Yousefnia*

Volume 16, Issue 2, 2023

Published on: 10 February, 2023

Page: [85 - 94] Pages: 10

DOI: 10.2174/1874471016666230106111119

Price: $65

conference banner
Abstract

This minireview describes the global situation of ongoing research and development and the clinical application of alpha emitter labeled immunoconjugates with various alpha emitters with an overview of the future trends. The potentially helpful alpha emitter radioisotopes for medical applications, chelators, and immunomolecules of interest for future alpha radioimmunotherapy are discussed. Challenges and some suggested future works on chelators are also presented.

Keywords: α-emitters, radio, immunotherapy, immunoconjugates, bifunctional ligands, trials.

« Previous
Graphical Abstract

[1]
Ménager, J.; Gorin, J-B.; Fichou, N.; Gouard, S.; Morgenstern, A.; Bruchertseifer, F.; Davodeau, F.; Kraeber-Bodéré, F.; Chérel, M.; Gaschet, J.; Guilloux, Y. Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity. Med. Sci. (Paris), 2016, 32(4), 362-369.
[PMID: 27137693]
[2]
Pandit-Taskar, N. Targeted radioimmunotherapy and theranostics with alpha emitters. J. Med. Imaging Radiat. Sci., 2019, 50(4)(Suppl. 1), S41-S44.
[http://dx.doi.org/10.1016/j.jmir.2019.07.006] [PMID: 31451417]
[3]
Nelson, B.J.B.; Andersson, J.D.; Wuest, F. TArgeted alpha therapy: progress in radionuclide production, radiochemistry, and applications. Pharmaceutics, 2020, 13(1), 49.
[http://dx.doi.org/10.3390/pharmaceutics13010049] [PMID: 33396374]
[4]
Dash, A.; Farahati, J.; Giammarile, F.; Jalilian, A.R. Production, quality control and clinical applications of radiosynovectomy agents, radioisot radiopharm reports; International Atomic Energy Agency, 2021.
[5]
Etchebehere, E.; Brito, A.E.; Rezaee, A.; Langsteger, W.; Beheshti, M. Therapy assessment of bone metastatic disease in the era of 223radium. Eur. J. Nucl. Med. Mol. Imaging, 2017, 44(S1)(Suppl. 1), 84-96.
[http://dx.doi.org/10.1007/s00259-017-3734-0] [PMID: 28567494]
[6]
Yang, H.; Wilson, J.J.; Orvig, C.; Li, Y.; Wilbur, D.S.; Ramogida, C.; Radchenko, V.; Schaffer, P. Harnessing alpha-emitting radionuclides for therapy: Radiolabeling method review. J. Nucl. Med., 2021.
[PMID: 34503958]
[7]
Clinicaltrial.gov 2021.
[8]
Radchenko, V.; Morgenstern, A.; Jalilian, A.R.; Ramogida, C.F.; Cutler, C.; Duchemin, C.; Hoehr, C.; Haddad, F.; Bruchertseifer, F.; Gausemel, H.; Yang, H.; Osso, J.A.; Washiyama, K.; Czerwinski, K.; Leufgen, K.; Pruszyński, M.; Valzdorf, O.; Causey, P.; Schaffer, P.; Perron, R.; Maxim, S.; Wilbur, D.S.; Stora, T.; Li, Y. Production and supply of a-particle–emitting radionuclides for targeted A-therapy. J. Nucl. Med., 2021, 62(11), 1495-1503.
[http://dx.doi.org/10.2967/jnumed.120.261016] [PMID: 34301779]
[9]
Adamiec, G.; Aitken, M.J. Dose-rate conversion factors: Update. Anc. TL, 1998, 16(2), 37-50.
[10]
Lowson, R.; Short, S. Analysis for the radionuclides of the natural uranium and thorium decay chains with special reference to uranium mine tailings; Australian Atomic Energy Commission: Sydney, 1986.
[11]
Tsuchikama, K.; An, Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell, 2018, 9(1), 33-46.
[http://dx.doi.org/10.1007/s13238-016-0323-0] [PMID: 27743348]
[12]
Chang, C-H.; Sharkey, R.M.; Rossi, E.A.; Karacay, H.; McBride, W.; Hansen, H.J.; Chatal, J-F.; Barbet, J.; Goldenberg, D.M. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol. Cancer Ther., 2002, 1(7), 553-563.
[PMID: 12479274]
[13]
Chapman, A.P.; Antoniw, P.; Spitali, M.; West, S.; Stephens, S.; King, D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol., 1999, 17(8), 780-783.
[http://dx.doi.org/10.1038/11717] [PMID: 10429243]
[14]
Kleiman, N. S.; Raizner, A. E.; Jordan, R.; Wang, A. L.; Norton, D.; Mace, K. F.; Joshi, A.; Coller, B. S.; Weisman, H. F. Differential Inhibition of Platelet Aggregation Induced by Adenosine Diphosphate or a Thrombin Receptor-Activating Peptide in Patients Treated with Bolus Chimeric 7E3 Fab: Implications for Inhibition of the Internal Pool of GPIIb/IIIa Receptors. J. Am. Coll. Cardiol., 1995, 26(7), 1665-1771.
[http://dx.doi.org/10.1016/0735-1097(95)00391-6]
[15]
Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol., 2009, 157(2), 220-233.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x] [PMID: 19459844]
[16]
Periodic Table of Antibodies. Absolute Antibody 2019. Available from: https://absoluteantibody.com/periodic-table-of-antibodies
[17]
Kannan, G.; Zhou, H.; Sun, N. Monomeric antibody Fc. US Patent 9200060, 2015.
[18]
Ahmad, Z.A.; Yeap, S.K.; Ali, A.M.; Ho, W.Y.; Alitheen, N.B.M.; Hamid, M. Antibody: principles and clinical application. Clin Dev Immunol., 2012, 2012
[19]
Robinson, H.R.; Qi, J.; Cook, E.M.; Nichols, C.; Dadashian, E.L.; Underbayev, C.; Herman, S.E.M.; Saba, N.S.; Keyvanfar, K.; Sun, C.; Ahn, I.E.; Baskar, S.; Rader, C.; Wiestner, A.A. CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Blood, 2018, 132(5), 521-532.
[http://dx.doi.org/10.1182/blood-2018-02-830992] [PMID: 29743179]
[20]
Hu, S.; Shively, L.; Raubitschek, A.; Sherman, M.; Williams, L.E.; Wong, J.Y.; Shively, J.E.; Wu, A.M. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res., 1996, 56(13), 3055-3061.
[PMID: 8674062]
[21]
Pothin, E.; Lesuisse, D.; Lafaye, P. Brain delivery of single-domain antibodies: A focus on VHH and VNAR. Pharmaceutics, 2020, 12(10), 937.
[http://dx.doi.org/10.3390/pharmaceutics12100937] [PMID: 33007904]
[22]
Hiltunen, J.V. Search for new and improved radiolabeling methods for monoclonal antibodies. A review of different methods. Acta Oncol., 1993, 32(7-8), 831-839.
[http://dx.doi.org/10.3109/02841869309096143] [PMID: 8305233]
[23]
Müller, C.; Vermeulen, C.; Köster, U.; Johnston, K.; Türler, A.; Schibli, R.; van der Meulen, N.P. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharm. Chem., 2017, 1(1), 5.
[http://dx.doi.org/10.1186/s41181-016-0008-2] [PMID: 29564382]
[24]
Chopra, A. 213Bi/211At-Labeled MX35, an anti– sodium-dependent phosphate transport protein 2b (NaPi2b) murine monoclonal antibody; Europepmc, 2012.
[25]
Allen, B.J.; Raja, C.; Rizvi, S.; Li, Y.; Tsui, W.; Zhang, D.; Song, E.; Qu, C.F.; Kearsley, J.; Graham, P.; Thompson, J. Targeted alpha therapy for cancer. Phys. Med. Biol., 2004, 49(16), 3703-3712.
[http://dx.doi.org/10.1088/0031-9155/49/16/016] [PMID: 15446799]
[26]
Mirzadeh, S.; Kennel, S.J. LNPO4 nanoparticles doped with AC-225 and sequestered daughters for targeted alpha therapy. Cancer Biother. Radiopharm., 2013, 29(1), 34-41.
[PMID: 24102173]
[27]
Hagemann, U.B.; Wickstroem, K.; Wang, E.; Shea, A.O.; Sponheim, K.; Karlsson, J.; Bjerke, R.M.; Ryan, O.B.; Cuthbertson, A.S. In vitro and in vivo efficacy of a novel CD33-targeted thorium-227 conjugate for the treatment of acute myeloid leukemia. Mol. Cancer Ther., 2016, 15(10), 2422-2431.
[http://dx.doi.org/10.1158/1535-7163.MCT-16-0251] [PMID: 27535972]
[28]
Frantellizzi, V.; Cosma, L.; Brunotti, G.; Pani, A.; Spanu, A.; Nuvoli, S.; De Cristofaro, F.; Civitelli, L.; De Vincentis, G. Targeted alpha therapy with thorium-227. Cancer Biother. Radiopharm., 2020, 35(6), 437-445.
[http://dx.doi.org/10.1089/cbr.2019.3105] [PMID: 31967907]
[29]
Guérard, F.; Gestin, J.F.; Brechbiel, M.W. Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. Cancer Biother. Radiopharm., 2013, 28(1), 1-20.
[http://dx.doi.org/10.1089/cbr.2012.1292] [PMID: 23075373]
[30]
Burtner, C.R.; Chandrasekaran, D.; Santos, E.B.; Beard, B.C.; Adair, J.E.; Hamlin, D.K.; Wilbur, D.S.; Sandmaier, B.M.; Kiem, H.P. 211Astatine-conjugated monoclonal CD45 antibody-based nonmyeloablative conditioning for stem cell gene therapy. Hum. Gene Ther., 2015, 26(6), 399-406.
[http://dx.doi.org/10.1089/hum.2015.021] [PMID: 25919226]
[31]
Feuerecker, B.; Biechl, P.; Seidl, C.; Bruchertseifer, F.; Morgenstern, A.; Schwaiger, M.; Eisenreich, W. Diverse metabolic response of cancer cells treated with a 213Bi-anti-EGFR-immunoconjugate. Sci. Rep., 2021, 11(1), 6227.
[http://dx.doi.org/10.1038/s41598-021-84421-4] [PMID: 33414495]
[32]
Minnix, M.; Li, L.; Yazaki, P.J.; Miller, A.D.; Chea, J.; Poku, E.; Liu, A.; Wong, J.Y.C.; Rockne, R.C.; Colcher, D.; Shively, J.E. TAG-72–Targeted a-radionuclide therapy of ovarian cancer using 225AC-labeled dotaylated-HUCC49 antibody. J. Nucl. Med., 2021, 62(1), 55-61.
[http://dx.doi.org/10.2967/jnumed.120.243394] [PMID: 32620701]
[33]
Bell, M.M.; Gutsche, N.T.; King, A.P.; Baidoo, K.E.; Kelada, O.J.; Choyke, P.L.; Escorcia, F.E. Glypican-3-targeted alpha particle therapy for hepatocellular carcinoma. Molecules, 2020, 26(1), 4.
[http://dx.doi.org/10.3390/molecules26010004] [PMID: 33374953]
[34]
Zalutsky, M.R.; Zhao, X-G.; Alston, K.L.; Bigner, D. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. J. Nucl. Med., 2001, 42(10), 1508-1515.
[PMID: 11585865]
[35]
Heskamp, S.; Hernandez, R.; Molkenboer-Kuenen, J.D.M.; Essler, M.; Bruchertseifer, F.; Morgenstern, A.; Steenbergen, E.J.; Cai, W.; Seidl, C.; McBride, W.J.; Goldenberg, D.M.; Boerman, O.C. A-versus B-emitting radionuclides for pretargeted radioimmunotherapy of carcinoembryonic antigen–expressing human colon cancer xenografts. J. Nucl. Med., 2017, 58(6), 926-933.
[http://dx.doi.org/10.2967/jnumed.116.187021] [PMID: 28232604]
[36]
Li, Y.; Tian, Z.; Rizvi, S.M.A.; Bander, N.H.; Allen, B.J. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis., 2002, 5(1), 36-46.
[http://dx.doi.org/10.1038/sj.pcan.4500543] [PMID: 15195129]
[37]
Friesen, C.; Glatting, G.; Koop, B.; Schwarz, K.; Morgenstern, A.; Apostolidis, C.; Debatin, K.M.; Reske, S.N. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res., 2007, 67(5), 1950-1958.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-3569] [PMID: 17332322]
[38]
Helal, M.; Allen, K.J.H.; Burgess, H.; Jiao, R.; Malo, M.E.; Hutcheson, M.; Dadachova, E.; Snead, E. Safety evaluation of an alpha-emitter bismuth-213 labeled antibody to (1→ 3)-B-glucan in healthy dogs as a prelude for a trial in companion dogs with invasive fungal infections. Molecules, 2020, 25(16), 3604.
[http://dx.doi.org/10.3390/molecules25163604] [PMID: 32784359]
[39]
Zhang, M.; Yao, Z.; Zhang, Z.; Garmestani, K.; Talanov, V.S.; Plascjak, P.S.; Yu, S.; Kim, H.S.; Goldman, C.K.; Paik, C.H.; Brechbiel, M.W.; Carrasquillo, J.A.; Waldmann, T.A. The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res., 2006, 66(16), 8227-8232.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-1189] [PMID: 16912202]
[40]
Takashima, H.; Koga, Y.; Manabe, S.; Ohnuki, K.; Tsumura, R.; Anzai, T.; Iwata, N.; Wang, Y.; Yokokita, T.; Komori, Y.; Mori, D.; Usuda, S.; Haba, H.; Fujii, H.; Matsumura, Y.; Yasunaga, M. Radioimmunotherapy with an 211 At‐labeled anti–tissue factor antibody protected by sodium ascorbate. Cancer Sci., 2021, 112(5), 1975-1986.
[http://dx.doi.org/10.1111/cas.14857] [PMID: 33606344]
[41]
Abbas Rizvi, S.M.; Henniker, A.J.; Goozee, G.; Allen, B.J. In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes. Leuk. Res., 2002, 26(1), 37-43.
[http://dx.doi.org/10.1016/S0145-2126(01)00096-0] [PMID: 11734302]
[42]
Chérel, M.; Gouard, S.; Gaschet, J.; Saï-Maurel, C.; Bruchertseifer, F.; Morgenstern, A.; Bourgeois, M.; Gestin, J.F.; Bodéré, F.K.; Barbet, J.; Moreau, P.; Davodeau, F. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J. Nucl. Med., 2013, 54(9), 1597-1604.
[http://dx.doi.org/10.2967/jnumed.112.111997] [PMID: 24003167]
[43]
Green, D.J.; Shadman, M.; Jones, J.C.; Frayo, S.L.; Kenoyer, A.L.; Hylarides, M.D.; Hamlin, D.K.; Wilbur, D.S.; Balkan, E.R.; Lin, Y.; Miller, B.W.; Frost, S.H.L.; Gopal, A.K.; Orozco, J.J.; Gooley, T.A.; Laird, K.L.; Till, B.G.; Bäck, T.; Sandmaier, B.M.; Pagel, J.M.; Press, O.W. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood, 2015, 125(13), 2111-2119.
[http://dx.doi.org/10.1182/blood-2014-11-612770] [PMID: 25628467]
[44]
Zalutsky, M.R.; Garg, P.K.; Friedman, H.S.; Bigner, D.D. Labeling monoclonal antibodies and F(ab’)2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc. Natl. Acad. Sci. USA, 1989, 86(18), 7149-7153.
[http://dx.doi.org/10.1073/pnas.86.18.7149] [PMID: 2476813]
[45]
Wilbur, D.S.; Vessella, R.L.; Stray, J.E.; Goffe, D.K.; Blouke, K.A.; Atcher, R.W. Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab′)2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab′)2. Nucl. Med. Biol., 1993, 20(8), 917-927.
[http://dx.doi.org/10.1016/0969-8051(93)90092-9] [PMID: 8298571]
[46]
Aurlien, E.; Larsen, R.H.; Kvalheim, G.; Bruland, Ø.S. Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate 211At-rituximab against non-Hodgkin’s lymphoma cells. Br. J. Cancer, 2000, 83(10), 1375-1379.
[http://dx.doi.org/10.1054/bjoc.2000.1453] [PMID: 11044364]
[47]
Demartis, S.; Tarli, L.; Borsi, L.; Zardi, L.; Neri, D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur. J. Nucl. Med., 2001, 28(4), 534-539.
[http://dx.doi.org/10.1007/s002590100480] [PMID: 11357506]
[48]
Palm, S.; Bäck, T.; Claesson, I.; Delle, U.; Hultborn, R.; Lindegren, S.; Jacobsson, L. Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention. Anticancer Res., 2003, 23(2B), 1219-1221.
[PMID: 12820374]
[49]
Henriksen, G.; Bruland, Ø.S.; Larsen, R.H. Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies. Anticancer Res., 2005, 25(1A), 9-15.
[PMID: 15816513]
[50]
Almqvist, Y.; Orlova, A.; Sjöström, A.; Jensen, H.J.; Lundqvist, H.; Sundin, A.; Tolmachev, V. In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma. Cancer Biother. Radiopharm., 2005, 20(5), 514-523.
[http://dx.doi.org/10.1089/cbr.2005.20.514] [PMID: 16248767]
[51]
Nestor, M.; Persson, M.; van Dongen, G.A.M.S.; Jensen, H.J.; Lundqvist, H.; Anniko, M.; Tolmachev, V. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2005, 32(11), 1296-1304.
[http://dx.doi.org/10.1007/s00259-005-1848-2] [PMID: 16028065]
[52]
Akabani, G.; Carlin, S.; Welsh, P.; Zalutsky, M.R. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl. Med. Biol., 2006, 33(3), 333-347.
[http://dx.doi.org/10.1016/j.nucmedbio.2005.12.006] [PMID: 16631082]
[53]
Andersson, H.; Palm, S.; Lindegren, S.; Bäck, T.; Jacobsson, L.; Leser, G.; Horvath, G. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. Anticancer Res., 2001, 21(1A), 409-412.
[PMID: 11299770]
[54]
Elgqvist, J.; Andersson, H.; Bäck, T.; Claesson, I.; Hultborn, R.; Jensen, H.; Johansson, B.R.; Lindegren, S.; Olsson, M.; Palm, S.; Warnhammar, E.; Jacobsson, L. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J. Nucl. Med., 2006, 47(8), 1342-1350.
[PMID: 16883015]
[55]
Wesley, J.N.; McGee, E.C.; Garmestani, K.; Brechbiel, M.W.; Yordanov, A.T.; Wu, C.; Gansow, O.A.; Eckelman, W.C.; Bacher, J.D.; Flynn, M.; Goldman, C.K.; MacLin, M.; Schwartz, U.P.; Jackson-White, T.; Phillip, C.M.; Decker, J.; Waldmann, T.A. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the α-emitting radionuclides 212Bi or 211At. Nucl. Med. Biol., 2004, 31(3), 357-364.
[http://dx.doi.org/10.1016/j.nucmedbio.2003.08.011] [PMID: 15028248]
[56]
Vaidyanathan, G.; Affleck, D.J.; Bigner, D.D.; Zalutsky, M.R. N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with α-particle emitting 211At. Nucl. Med. Biol., 2003, 30(4), 351-359.
[http://dx.doi.org/10.1016/S0969-8051(03)00005-2] [PMID: 12767391]
[57]
Vaidyanathan, G.; Pozzi, O.R.; Choi, J.; Zhao, X.G.; Murphy, S.; Zalutsky, M.R. Labeling monoclonal antibody with a-emitting 211at at high activity levels via a tin precursor. Cancer Biother. Radiopharm., 2020, 35(7), 511-519.
[http://dx.doi.org/10.1089/cbr.2019.3204] [PMID: 32109139]
[58]
Atallah, E.L.; Orozco, J.J.; Craig, M.; Levy, M.Y.; Finn, L.E.; Khan, S.S.; Perl, A.E.; Park, J.H.; Roboz, G.J.; Tse, W.; Begna, K.H.; Mawad, R.; Rizzieri, D.A.; Berger, M.S.; Jurcic, J.G. A phase 2 study of actinium-225 (225AC)-lintuzumab in older patients with untreated acute myeloid leukemia (aml)-interim analysis of 1.5 µci/kg/dose. Blood, 2018, 132(Suppl. 1), 1457.
[http://dx.doi.org/10.1182/blood-2018-99-111951]
[59]
Autenrieth, M.E.; Seidl, C.; Bruchertseifer, F.; Horn, T.; Kurtz, F.; Feuerecker, B.; D’Alessandria, C.; Pfob, C.; Nekolla, S.; Apostolidis, C.; Mirzadeh, S.; Gschwend, J.E.; Schwaiger, M.; Scheidhauer, K.; Morgenstern, A. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study. Eur. J. Nucl. Med. Mol. Imaging, 2018, 45(8), 1364-1371.
[http://dx.doi.org/10.1007/s00259-018-4003-6] [PMID: 29644393]
[60]
McDevitt, M.R.; Finn, R.D.; Ma, D.; Larson, S.M.; Scheinberg, D.A. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. J. Nucl. Med., 1999, 40(10), 1722-1727.
[PMID: 10520715]
[61]
Meredith, R.; Torgue, J.; Shen, S.; Fisher, D.R.; Banaga, E.; Bunch, P.; Morgan, D.; Fan, J.; Straughn, J.M. Jr Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. J. Nucl. Med., 2014, 55(10), 1636-1642.
[http://dx.doi.org/10.2967/jnumed.114.143842] [PMID: 25157044]
[62]
Andersson, H.; Cederkrantz, E.; Bäck, T.; Divgi, C.; Elgqvist, J.; Himmelman, J.; Horvath, G.; Jacobsson, L.; Jensen, H.; Lindegren, S.; Palm, S.; Hultborn, R. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab’)2--a phase I study. J. Nucl. Med., 2009, 50(7), 1153-1160.
[http://dx.doi.org/10.2967/jnumed.109.062604] [PMID: 19525452]
[63]
Li, Y.; Hamlin, D.K.; Chyan, M.K.; Wong, R.; Dorman, E.F.; Emery, R.C.; Woodle, D.R.; Manger, R.L.; Nartea, M.; Kenoyer, A.L.; Orozco, J.J.; Green, D.J.; Press, O.W.; Storb, R.; Sandmaier, B.M.; Wilbur, D.S. cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies. PLoS One, 2018, 13(10), e0205135.
[http://dx.doi.org/10.1371/journal.pone.0205135] [PMID: 30335787]
[64]
Nunez, R. Targeted alpha therapy with 225Actinium- PSMA-I&T of Castration- resistant Prostate Cancer (TATCIST). NCT0521 9500, 2022.
[65]
EPIX, a study to gather more information about characteristics of patients and other factors which may contribute to survival over a long period of time in patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223. NCT04516161, 2022.
[66]
Subbiah, V. Phase I dose escalation of monthly intravenous Ra-223 dichloride in osteosarcoma. NCT01833520, 2022.
[67]
Olmos, D; Castro, E.; Morales, R.; Saez, M.I. PRORADIUM: Prospective multi-centre study of prognostic factors in mCRPC patients treated with radium-223. NCT02925702, 2020.
[68]
Eisenberger, M. A Study of radium-223 in combination with tasquinimod in bone only metastatic castration-resistant prostate cancer. NCT02396368, 2015.

Rights & Permissions Print Cite
Article Metrics
46
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy